SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-001682
Filing Date
2022-01-04
Accepted
2022-01-04 16:05:59
Documents
13
Period of Report
2021-12-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K d263245d8k.htm   iXBRL 8-K 35264
  Complete submission text file 0001193125-22-001682.txt   193858

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ziop-20211228.xsd EX-101.SCH 3215
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ziop-20211228_def.xml EX-101.DEF 13697
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ziop-20211228_lab.xml EX-101.LAB 22617
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ziop-20211228_pre.xml EX-101.PRE 14555
7 EXTRACTED XBRL INSTANCE DOCUMENT d263245d8k_htm.xml XML 5032
Mailing Address ONE FIRST AVENUE PARRIS BUILDING 34, NAVY YARD PLAZA BOSTON MA 02129
Business Address ONE FIRST AVENUE PARRIS BUILDING 34, NAVY YARD PLAZA BOSTON MA 02129 617-259-1970
ZIOPHARM ONCOLOGY INC (Filer) CIK: 0001107421 (see all company filings)

IRS No.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33038 | Film No.: 22505805
SIC: 2834 Pharmaceutical Preparations